What it's for (Indications)
- Brinzolamide ophthalmic suspension is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- As a carbonic anhydrase inhibitor (CAI), brinzolamide works by reducing the rate of aqueous humor production in the ciliary body of the eye, thereby decreasing the pressure within the eye.
- This therapeutic action is crucial for preventing progressive optic nerve damage and vision loss associated with sustained elevated IOP.
- Its use is typically considered when monotherapy with prostaglandin analogs or beta-blockers is insufficient, or when these agents are contraindicated or not tolerated by the patient.
- The reduction in IOP achieved with brinzolamide is a key aspect of managing these chronic ocular conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, the recommended dosage of brinzolamide ophthalmic suspension is one drop in the affected eye(s) three times daily (TID). Patients should be instructed to shake the bottle well before each use to ensure proper suspension of the active ingredient. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart to prevent washout and ensure optimal absorption. It is crucial for patients to adhere strictly to the prescribed dosing regimen and instillation technique to achieve and maintain the desired therapeutic effect and minimize potential fluctuations in intraocular pressure. Missed doses should be administered as soon as remembered, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped. |
Safety & Warnings
Common Side Effects
- Common ocular adverse reactions reported with brinzolamide ophthalmic suspension include blurred vision, eye irritation, discomfort, stinging or burning upon instillation, foreign body sensation, dry eye, ocular pruritus, and conjunctival hyperemia.
- Other less common ocular effects may include blepharitis, keratitis, corneal erosion, and crusting or discharge from the eye.
- Systemic adverse reactions, while generally less frequent and severe than with oral carbonic anhydrase inhibitors due to limited systemic absorption, can occur.
- The most commonly reported systemic side effect is dysgeusia (a bitter, sour, or unusual taste in the mouth).
- Other systemic effects may include headache, nausea, fatigue, pharyngitis, and sinusitis.
- Patients should be advised to report any persistent or severe adverse effects to their healthcare provider.
- Allergic reactions, including rash, urticaria, and, rarely, more severe systemic reactions typical of sulfonamides, are also possible and warrant immediate medical attention.
Serious Warnings
- Black Box Warning: While Brinzolamide (Azopt) does not carry an FDA Black Box Warning, the following serious warnings are critical for prescribers and patients to consider due to potential high-risk factors: **SERIOUS WARNINGS: SULFONAMIDE HYPERSENSITIVITY REACTIONS:** Brinzolamide is a sulfonamide. Although administered topically, systemic absorption occurs. Therefore, patients with a known history of severe, potentially life-threatening hypersensitivity reactions to sulfonamides (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, or other blood dyscrasias) should exercise extreme caution. There is a potential for similar severe, albeit rare, systemic adverse reactions to occur with ophthalmic brinzolamide. Close monitoring for signs of systemic adverse reactions, including dermatologic, hematologic, hepatic, or renal effects, is imperative, and the drug should be discontinued immediately if such reactions are suspected. Patients should be thoroughly educated about these risks. **RISK OF SYSTEMIC ACID-BASE DISTURBANCES:** As a carbonic anhydrase inhibitor, brinzolamide can cause systemic acid-base disturbances, particularly in patients with pre-existing renal impairment or those prone to metabolic acidosis. While the risk of significant systemic acidosis is lower with topical administration compared to oral CAIs, it remains a serious concern, especially in vulnerable populations (e.g., patients with severe renal insufficiency [CrCl < 30 mL/min] or conditions predisposing to acidosis). Regular monitoring of acid-base status may be warranted in these high-risk patients. The drug is contraindicated in severe renal impairment and hyperchloremic acidosis. **CORNEAL ENDOTHELIAL DECOMPENSATION:** Carbonic anhydrase inhibitors have been shown to affect corneal endothelial function. Patients with pre-existing corneal compromise, such as those with corneal dystrophies, low endothelial cell counts, or who have recently undergone intraocular surgery, may be at an increased risk for corneal edema or decompensation. Prescribers should carefully assess the corneal health of patients prior to initiating therapy and during treatment, particularly in those with predisposing factors for corneal compromise. Discontinuation of brinzolamide should be considered if signs of corneal decompensation appear.
- Brinzolamide is a sulfonamide and, although administered topically, it is absorbed systemically.
- Therefore, patients with a history of severe hypersensitivity reactions to sulfonamides (e.
- g.
- , Stevens-Johnson syndrome, toxic epidermal necrolysis, blood dyscrasias) should be closely monitored and educated on the potential for similar systemic adverse reactions.
- The drug has not been studied in patients with acute angle-closure glaucoma; its use in this condition is not recommended.
- Caution is advised in patients with compromised corneal endothelium (e.
- g.
- , low endothelial cell count, corneal dystrophies) due to potential effects on corneal function.
- Contact lenses should be removed prior to instillation and may be reinserted 15 minutes after administration.
- Systemic absorption can lead to acid-base disturbances, particularly in patients with severe renal impairment (CrCl < 30 mL/min) or pre-existing metabolic acidosis.
- Transient blurred vision may impair the ability to drive or operate machinery.
- Pregnancy Category C; use only if the potential benefit justifies the potential risk to the fetus.
- It is unknown whether brinzolamide is excreted in human milk, and caution should be exercised when administered to a nursing mother.
- The safety and efficacy in pediatric patients have not been established.
How it Works (Mechanism of Action)
Brinzolamide is a highly potent, reversible inhibitor of carbonic anhydrase (CA), specifically the isoenzyme carbonic anhydrase II (CA-II), which is predominantly found in the ciliary body of the eye. In the ciliary processes, carbonic anhydrase catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. This enzymatic activity is integral to the formation of bicarbonate ions, which in turn facilitate the active transport of sodium and water from the blood into the posterior chamber, leading to the production of aqueous humor. By inhibiting carbonic anhydrase in the ciliary epithelium, brinzolamide effectively reduces the formation of bicarbonate ions, consequently decreasing the secretion of aqueous humor. This reduction in aqueous humor inflow directly leads to a significant decrease in intraocular pressure (IOP), which is the primary therapeutic goal in managing open-angle glaucoma and ocular hypertension. The topical application of brinzolamide allows for localized action with reduced systemic side effects compared to oral carbonic anhydrase inhibitors.
Commercial Brands (Alternatives)
No other brands found for this formula.